Application of lipoarabinomannan antigen in tuberculosis diagnostics: Current evidence

Postgraduate Medical Journal

Volumn 90, Issue 1061, 2014, Pages 155-163

  Sarkar, Pronoti ^a   Biswas, Debasis ^a,b   Sindhwani, Girish ^a   Rawat, Jagdish ^a   Kotwal, Aarti ^a   Kakati, Barnali ^a  

^a HIMALAYAN INSTITUTE OF MEDICAL SCIENCES   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; LIPOARABINOMANNAN ANTIGEN; PULMONARY TUBERCULOSIS;

CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV SEROPOSITIVITY; HUMANS; LIPOPOLYSACCHARIDES; MALE; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; PREVALENCE; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS;

EID: 84894288884     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2013-132053     Document Type: Review

References (65)

1. World Health Organization. Global tuberculosis report 2013. http://www.who.int/tb/ publications/global_report/gtbr13_executive_summary.pdf (accessed 8 Dec 2013).
2. World Health Organization. The Stop TB Strategy. http://www.who.int/tb/strategy/ stop_tb_strategy/en/index.html (accessed 6 Sep 2012).
3. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:664-74.
4. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007;369:2042-9.
5. Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011;134:850-65.
6. Churchyard G, Fielding KL, Lewis JJ, et al. Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. AIDS 2010;24:S19-2749.
7. World Health Organization. TB Diagnostics and Laboratory Services: Information note. http://www.who.int/tb/dots/lab.pdf (accessed 6 Sep 2012).
8. Flores LL, Steingart KR, Dendukuri N, et al. Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis. Clin Vaccine Immunol 2011;18:1616-27.
9. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009;9:173-84.
10. Lawn SD, Kerkhoff AD, Vogt M, et al. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012;12:201-9.
11. Dheda K, Davids V, Lenders L, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS ONE 2010;5:e9848.
12. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012;12:103.
13. Hunter SW, Gaylord H, Brennan PJ. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem 1986;261:12345-51.
14. Pereira Arias-Bouda LM, Nguyen LN, Ho LM, et al. Development of antigen detection assay for diagnosis of tuberculosis using sputum samples. J Clin Microbiol 2000;38:2278-83.
15. Vercellone A, Nigou J, Puzo G. Relationships between the structure and the roles of lipoarabinomannans and related glycoconjugates in tuberculosis pathogenesis. Front Biosci 1998;3:e149-63.
16. Khoo KH, Tang JB, Chatterjee D. Variation in mannose-capped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex. J Biol Chem 2001;276:3863-71.
17. Guérardel Y, Maes E, Briken V, et al. Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii: novel structural features and apoptosis-inducing properties. J Biol Chem 2003;278:36637-51.
18. Khoo KH, Dell A, Morris HR, et al. Inositol phosphate capping of the non reducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium. J Biol Chem 1995;270:12380-9.
19. Guerardel Y, Maes E, Elass E, et al. Structural study of lipomannan and lipoarabinomannan from Mycobacterium chelonae. Presence of unusual components with alpha 1,3-mannopyranose side chains. J Biol Chem 2002;277:30635-48.
20. Chatterjee D, Khoo KH. Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. Glycobiology 1998;8:113-20.
21. Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect 1999;1:709-17.
22. Rojas M, García LF, Nigou J, et al. Mannosylated lipoarabinomannan antagonizes Mycobacterium tuberculosis-induced macrophage apoptosis by altering Ca +2-dependent cell signalling. J Infect Dis 2000;182:240-51.
23. Rojas M, Barrera LF, Puzo G, et al. Differential induction of apoptosis by virulent Mycobacterium tuberculosis in resistant and susceptible murine macrophages: role of nitric oxide and mycobacterial products. J Immunol 1997;159:1352-61.
24. Knutson KL, Hmama Z, Herrera-Velit P, et al. Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1. J Biol Chem 1998;273: 645-52.
25. Fratti RA, Backer JM, Gruenberg J, et al. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 2001;154:631-44.
26. Fratti RA, Chua J, Vergne I, et al. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci USA 2003;100:5437-42.
27. Geijtenbeek TB, Van Vliet SJ, Koppel EA, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003;197:7-17.
28. Garg A, Barnes PF, Roy S, et al. Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent expansion of regulatory T cells in human Mycobacterium tuberculosis infection. Eur J Immunol 2008;38:459-69.
29. Bhattacharya A, Ranadive SN, Kale M, et al. Antibody-based enzyme-linked immunosorbent assay for determination of immune complexes in clinical tuberculosis. Am Rev Respir Dis 1986;134:205-9.
30. Hamasur B, Bruchfeld J, Haile M, et al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J Microbiol Methods 2001;45:41-52.
31. Glatman-Freedman A, Mednick AJ, Lendvai N, et al. Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M. Infect Immun 2000;68:335-41.
32. Wood R, Racow K, Bekker LG, et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis 2012;12:47.
33. Boehme C, Molokova E, Minja F, et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 2005;99:893-900.
34. Sittampalam GS, Smith WC, Miyakawa TW, et al. Application of experimental design techniques to optimize a competitive ELISA. J Immunol Methods 1996;190:151-61.
35. Peter J, Green C, Hoelscher M, et al. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010;16:262-70.
36. Lawn SD, Edwards DJ, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009;23:1875-80.
37. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr 2009;52:145-51.
38. Peter JG, Theron G, van Zyl-Smit R, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J 2012;40:1211-20.
39. Sarkar S, Tang XL, Das D, et al. A bispecific antibody based assay shows potential for detecting tuberculosis in resource constrained laboratory settings. PLoS ONE 2012;7:e32340.
40. Bhatnagar PK, Das D, Suresh MR. Sequential affinity purification of peroxidase tagged bispecific anti-SARS CoV antibodies on phenylboronic acid agarose. J Chromatogr B Analyt Technol Biomed Life Sci 2008;863:235-41.
41. Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011;38:1398-405.
42. Wood R, Lawn SD. Challenges facing lipoarabinomannan urine antigen tests for diagnosing HIV-associated tuberculosis. Expert Rev Mol Diagn 2012;12: 549-51.
43. Lipman NS, Jackson LR, Trudel LJ, et al. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications and information reasources. ILAR J 2005;46:943-54.
44. Ritter MA. Polyclonal and monoclonal antibodies. Methods Mol Med 2000;40:23-34.
45. Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS ONE 2012;7:e32876.
46. Shah M, Martinson NA, Chaisson RE, et al. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol 2010;48:2972-4.
47. Roberts-Thomsom PJ, Shepherd K. Molecular size heterogeneity of immunoglobulins in health and disease. Clin Exp Immunol 1990;79:328-34.
48. Doublier S, Zennaro C, Spatola T, et al. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007;21:423-32.
49. Peter JG, Theron G, Muchinga TE, et al. The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS ONE 2012;7:e39966.
50. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin. Infect Dis 2012;54:1071-9.
51. Reither K, Saathoff E, Jung J, et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis 2009;9:141.
52. Mutetwa R, Boehme C, Dimairo M, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis 2009;13:1253-9.
53. Gounder CR, Kufa T, Wada NI, et al. Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr 2011;58:219-23.
54. Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009;180:903-8.
55. Kadival GV, Mazarelo TB, Chaparas SD. Sensitivity and specificity of enzyme-linked immunosorbent assay in the detection of antigen in tuberculous meningitis cerebrospinal fluids. J ClinMicrobiol 1986;23:901-4.
56. Dorman S, Manabe Y, Nicol M, et al. Accuracy of determine TB-LAM lateral flow test for diagnosis of TB in HIV + adults: interim results from a multicenter study. Seattle, Washington: Program and Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections, 2012; Abstract #149aLB.
57. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis 2013;13:407.
58. Alere. Alere Determine™ TB LAM Ag. http://www.alere.com/ww/en/product-details/ determine-tb-lam.html (accessed 25 Sep 2013).
59. Lawn SD, Kerkhoff AD, Vogt M, et al. Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis. AIDS 2012;26:1635-43.
60. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS ONE 2013;8:e54875.
61. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF System Policy Statement. http:// whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf (accessed 28 Jun 2011).
62. Patel VB, Bhigjee AI, Paruk HF, et al. Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Res 2009;6:13.
63. Patel VB, Singh R, Connolly C, et al. Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting. PLoS ONE 2010;5:e15664.
64. Cho SN, Shin JS, Kim JD, et al. Production of monoclonal antibodies to lipoarabinomannan-B and use in the detection of mycobacterial antigens in sputum. Yonsei Med J 1990;31:333-8.
65. Daley P, Michael JS, Hmar P, et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis 2009;13:989-95.